ATE518854T1 - Arylcarbonsäurecyclohexylamidderivate - Google Patents

Arylcarbonsäurecyclohexylamidderivate

Info

Publication number
ATE518854T1
ATE518854T1 AT08709083T AT08709083T ATE518854T1 AT E518854 T1 ATE518854 T1 AT E518854T1 AT 08709083 T AT08709083 T AT 08709083T AT 08709083 T AT08709083 T AT 08709083T AT E518854 T1 ATE518854 T1 AT E518854T1
Authority
AT
Austria
Prior art keywords
arylcarboxic
acidcyclohexylamide
derivatives
arylcarboxic acidcyclohexylamide
acidcyclohexylamide derivatives
Prior art date
Application number
AT08709083T
Other languages
English (en)
Inventor
Rene Hersperger
Philipp Janser
Wolfgang Miltz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE518854T1 publication Critical patent/ATE518854T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT08709083T 2007-02-19 2008-02-18 Arylcarbonsäurecyclohexylamidderivate ATE518854T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07102622 2007-02-19
PCT/EP2008/051951 WO2008101905A1 (en) 2007-02-19 2008-02-18 Aryl carboxylic acid cyclohexyl amide derivatives

Publications (1)

Publication Number Publication Date
ATE518854T1 true ATE518854T1 (de) 2011-08-15

Family

ID=38058317

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08709083T ATE518854T1 (de) 2007-02-19 2008-02-18 Arylcarbonsäurecyclohexylamidderivate

Country Status (35)

Country Link
US (1) US8354431B2 (de)
EP (1) EP2125782B1 (de)
JP (1) JP5180234B2 (de)
KR (1) KR101070984B1 (de)
CN (1) CN101605781B (de)
AR (1) AR065369A1 (de)
AT (1) ATE518854T1 (de)
AU (1) AU2008219317B2 (de)
BR (1) BRPI0807625A2 (de)
CA (1) CA2677565C (de)
CL (1) CL2008000497A1 (de)
CR (1) CR10957A (de)
CY (1) CY1111984T1 (de)
DK (1) DK2125782T3 (de)
EA (1) EA017000B1 (de)
EC (1) ECSP099584A (de)
ES (1) ES2371126T3 (de)
GT (1) GT200900226A (de)
HN (1) HN2009001607A (de)
HR (1) HRP20110793T1 (de)
IL (1) IL200191A (de)
MA (1) MA31206B1 (de)
MX (1) MX2009008145A (de)
MY (1) MY147487A (de)
NZ (1) NZ578663A (de)
PE (1) PE20081785A1 (de)
PL (1) PL2125782T3 (de)
PT (1) PT2125782E (de)
RS (1) RS51986B (de)
SI (1) SI2125782T1 (de)
TN (1) TN2009000345A1 (de)
TW (1) TW200848038A (de)
UA (1) UA97389C2 (de)
WO (1) WO2008101905A1 (de)
ZA (1) ZA200905160B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3532570B2 (ja) 1994-01-13 2004-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 哺乳類単球化学誘引物質タンパク質レセプター
ATE428785T1 (de) 1996-03-01 2009-05-15 Euroscreen Sa Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren
AU3375697A (en) 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
US6388055B1 (en) 1996-10-03 2002-05-14 Smithkline Beecham Corporation Mouse CC-CKR5 receptor polypeptide
AR008331A1 (es) 1997-01-23 1999-12-29 Smithkline Beecham Corp Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen
WO1999032100A2 (en) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
EP1140896A1 (de) 1998-12-21 2001-10-10 Takeda Chemical Industries, Ltd. Benzothiepin-anilid derivate, ihre herstellung und ihre verwendung als ccr-5 antagonisten
AU2000227285A1 (en) 2000-01-14 2001-07-24 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods of regulating il-12 production by administering ccr5 agonists and antagonists
RU2252786C2 (ru) 2000-09-08 2005-05-27 Микромет Аг Конструкции антител и хемокинов и их применение при иммунологических нарушениях
NZ532018A (en) 2001-10-03 2004-12-24 Ucb S Pyrrolidinone derivatives
US20060251651A1 (en) 2002-12-13 2006-11-09 Ono Pharmaceutical Co., Ltd. Antagonist and agonist which bind to a strong binding site of chemokine receptor
WO2004098638A1 (ja) 2003-05-06 2004-11-18 Ono Pharmaceutical Co., Ltd. エフェクター細胞機能阻害剤
GB2423472A (en) 2003-12-11 2006-08-30 Univ Yale Methods and compositions relating to ccr5 antagonist,ifn-&gammed;and il-13 induced inflammation
CA2550596C (en) * 2003-12-18 2011-03-15 Incyte Corporation 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
GB0403038D0 (en) * 2004-02-11 2004-03-17 Novartis Ag Organic compounds
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CN1950085A (zh) * 2004-05-11 2007-04-18 因赛特公司 作为趋化因子受体调节剂的3－(4－杂芳基环己基氨基)环戊烷羧酰胺
GB0412468D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
WO2007062175A2 (en) 2005-11-21 2007-05-31 Amgen Inc. Spiro-substituted tricyclic heterocycles cxcr3 antagonists
GB0525957D0 (en) 2005-12-21 2006-02-01 Astrazeneca Ab Methods
KR20090013827A (ko) 2006-06-12 2009-02-05 화이자 프로덕츠 인크. Ｈｉｖ 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ｃｃｒ５ 길항제
US20080076120A1 (en) 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
BRPI0718225A2 (pt) 2006-10-05 2013-11-12 Centocor Ortho Biotech Inc Antagonistas de ccr2 para tratamento de fibrose
US20100210633A1 (en) 2006-10-12 2010-08-19 Epix Delaware, Inc. Carboxamide compounds and their use
MX2009005252A (es) 2006-11-17 2009-05-28 Abbott Lab Aminopirrolidinas como antagonistas del receptor de quimiocina.
US20100267765A1 (en) 2007-02-15 2010-10-21 Stephen John Felstead Pharmaceutical Compositions and Methods for CCR5 Antagonists
EP2150817A4 (de) 2007-04-30 2011-09-07 Progenics Pharm Inc Verfahren zur reduktion der viruslast bei hiv-1-infizierten patienten

Also Published As

Publication number Publication date
KR101070984B1 (ko) 2011-10-06
CN101605781A (zh) 2009-12-16
CA2677565A1 (en) 2008-08-28
TW200848038A (en) 2008-12-16
HN2009001607A (es) 2011-11-23
AR065369A1 (es) 2009-06-03
ES2371126T3 (es) 2011-12-27
EP2125782A1 (de) 2009-12-02
JP2010519187A (ja) 2010-06-03
IL200191A (en) 2013-12-31
MA31206B1 (fr) 2010-02-01
AU2008219317B2 (en) 2011-09-08
EA017000B1 (ru) 2012-09-28
CY1111984T1 (el) 2015-11-04
RS51986B (sr) 2012-02-29
US8354431B2 (en) 2013-01-15
ZA200905160B (en) 2010-05-26
BRPI0807625A2 (pt) 2014-05-27
CN101605781B (zh) 2014-08-13
HK1138836A1 (en) 2010-09-03
SI2125782T1 (sl) 2011-12-30
NZ578663A (en) 2011-01-28
MY147487A (en) 2012-12-14
HRP20110793T1 (hr) 2011-11-30
PT2125782E (pt) 2011-11-17
TN2009000345A1 (en) 2010-12-31
US20100016361A1 (en) 2010-01-21
CR10957A (es) 2009-09-01
EA200901085A1 (ru) 2010-02-26
GT200900226A (es) 2010-07-02
CA2677565C (en) 2014-11-18
DK2125782T3 (da) 2011-11-21
WO2008101905A1 (en) 2008-08-28
UA97389C2 (en) 2012-02-10
KR20090103943A (ko) 2009-10-01
ECSP099584A (es) 2009-09-29
IL200191A0 (en) 2010-04-15
PE20081785A1 (es) 2009-01-12
EP2125782B1 (de) 2011-08-03
CL2008000497A1 (es) 2008-08-29
PL2125782T3 (pl) 2011-12-30
JP5180234B2 (ja) 2013-04-10
MX2009008145A (es) 2009-08-12
AU2008219317A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
CY2024031I1 (el) Παραγωγο 4-πυριμιδινοσουλφαμιδης
DK2164844T3 (da) Pyrimidinyl-pyridazinonderivater
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
BRPI0813836A2 (pt) Derivados pirazólicos
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0817935A2 (pt) Derivados de biarila
ATE518837T1 (de) Indazolamidderivate
DK2308877T3 (da) Imidazopyridin-2-on-derivater
DK2016080T3 (da) Dihydropyrazolopyrimidinon-derivater
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
EP2226315A4 (de) 2-aminochinazolin-derivat
DK2152370T3 (da) Aryletherpyridazinonderivater
BRPI0814236A2 (pt) Derivados de quinazolinamida
DK2035394T3 (da) 2-pyrazincarboxamidderivater
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
DK2275414T3 (da) Cyclopentylacrylamidderivat
DK2086968T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
BRPI0812994A2 (pt) Microbiocidas
ATE519760T1 (de) Isoxazolimidazolderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2125782

Country of ref document: EP